RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., a leading diagnostics and research services company offering metabolomics research platforms, has entered into a collaboration with GlaxoSmithKline (GSK) to provide metabolomic profiling services and to collaborate on other research projects leveraging Metabolon's leading DiscoveryHD4™ platform.
The collaboration will give GSK access to Metabolon's bioinformatics tools along with the company's proprietary disease ontologies, as well as visualization tools that will integrate metabolomics data with existing genomics and proteomics data. John Ryals, Metabolon President and CEO commented, "We are pleased to announce a collaboration with GSK. We believe that embedding metabolomic profiling capabilities at the various stages of R&D is important to enhance the phenotypic 'picture' with the aim of yielding translatable, meaningful results. Gaps of knowledge can be bridged through the understanding metabolomics provides, which could lead to better targets, higher quality molecules, faster time to the clinic and reduced risk and cost."
Metabolon, Inc. has completed thousands of metabolomics studies across numerous therapeutic areas and has developed expertise in metabolic pathways and targets that are involved in the onset of disease and its progression. Metabolon's technology platforms are robust and known for their rapid, repeatable results. Expert, credentialed biochemists interpret biological data to yield actionable insight into key disease metabolic processes, drug action, and patient response.
Metabolon is a world-leading, commercial-stage metabolomics company. Metabolomics is a rapidly evolving field of biochemical research and discovery focused on the measurement of small molecules involved in metabolism. Metabolon's proprietary metabolomics technology maps these small molecule pathways to identify diseases, discover biomarkers, and better understand complex biological processes. The company's Metabolytics business uses its proprietary metabolomics technology to conduct sponsored studies for life sciences researchers in industry and academia, which provide insight into complex biochemical processes. Data from these studies are used to populate Metabolon's large and growing metabolomic information and pathway knowledge databases, which generate new product ideas for the company's Diagnostics business. For more information, visit www.metabolon.com, or email [email protected] or call 919-287-3364.
Metabolon Cautionary Note about Forward-Looking Statements
The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties, and assumptions. If any of these risks or uncertainties materializes or if any of these assumptions prove incorrect, the results of Metabolon could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties, and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; our and our partners' ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including regarding access, pricing and reimbursement of diagnostic tests; the strength of our intellectual property portfolio; our history of losses; whether we are able to achieve or sustain profitability; our highly competitive industry; our ability to compete effectively; security and privacy risks; and our ability to continue to innovate and provide products and services that are useful to our clients, among other risks, uncertainties, and assumptions.